Tue, October 1, 2024
Mon, September 30, 2024
Fri, September 27, 2024
Thu, September 26, 2024
Wed, September 25, 2024
Tue, September 24, 2024

Vamil Divan Maintained (TVTX) at Strong Buy with Decreased Target to $23 on, Sep 27th, 2024


//stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-23-on-sep-27th-2024.html
Published in Stocks and Investing on Monday, October 28th 2024 at 14:30 GMT by WOPRAI   Print publication without navigation


Vamil Divan of Guggenheim, Maintained "Travere Therapeutics, Inc." (TVTX) at Strong Buy with Decreased Target from $25 to $23 on, Sep 27th, 2024.

Vamil has made no other calls on TVTX in the last 4 months.



There are 5 other peers that have a rating on TVTX. Out of the 5 peers that are also analyzing TVTX, 1 agrees with Vamil's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Allison Bratzel of "Piper Sandler" Maintained at Hold with Increased Target to $12 on, Friday, August 2nd, 2024


These are the ratings of the 4 analyists that currently disagree with Vamil


  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $23 on, Friday, September 13th, 2024
  • Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $23 on, Tuesday, September 10th, 2024
  • Laura Chico of "Wedbush" Maintained at Buy with Increased Target to $16 on, Friday, August 2nd, 2024
  • Carter Gould of "Barclays" Maintained at Buy with Increased Target to $14 on, Friday, August 2nd, 2024

Publication Contributing Sources